ECTE is My Next HUGE Biotech Stock
————————————————————-
My Next Huge Biotech Stock is…
*** Echo Therapeutics (OTCBB: ECTE) ***
ECTE believes that the Symphony tCGM System will change the paradigm of invasive, needle-based, pisodic glucose testing in the diabetes consumer and hospital critical care markets to one of continuous, eedle-free monitoring.
ECTE is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation to allow for transdermal drug delivery of a wide range of FDA-approved products.
The continuous monitoring will enable more accurate management of diabetes (resulting in healthier outcomes) and higher compliance compared to painful, invasive methods for drawing blood today.
ECTE also believes that its Prelude SkinPrep System will allow many drugs currently delivered by needle injection to be administered without a needle by using Prelude prior to transdermal drug administration.
———————————-
ECTE has signed a $15 million agreement, giving Ferndale Pharmaceuticals a license to develop, market and sell Prelude for enhanced delivery of Ferndale’s topical lidocaine product, LMX4, in North America and the UK. Echo received $750,000 up front and will receive $750,000 upon FDA approval, as well as $12.5 million in milestones and guaranteed minimum royalty payments. Echo will also receive a double digit royalty on
net sales of the product.
- Non-invasive, wireless, continuous blood glucose monitoring system
- Utilizes Prelude™ SkinPrep, a novel, needle-free platform technology that increases skin permeability
- Efficient, remote monitoring platform compared to platforms using needle-basedtechnologies for accuracy
- Low manufacturing cost and a razor/razor blade model with a single-use consumable
- Readings obtained every minute with wireless data transmission to portable monitor
- Short, one-hour warm-up
- Six consecutive positive pilot studies in glucose monitoring to date
- 510-k filing in 1Q10 for Prelude with the use of lidocaine
- Prelude lidocaine sales offer best near-term revenue opportunity
- Minimum sales would reduce cash burn and move company toward cash flow positive business
- Revenues projected to begin during 2Q10
- Pivotal trial and PMA filing for Symphony™ anticipated in 2010 for glucose monitoring
- Symphony™ tCGM licensed in South Korea to Handok Pharmaceuticals
I’ve mentioned that there are some stocks that perform extremely well because they are "Story Stocks" whose one-of-a-kind, unique technology is intriguing and special enough that it makes entertaining discussions for those not even involved in development-stage companies that are abundant in the OTC/OTCBB Markets.
otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. LiquidTycoon’s affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. LiquidTycoon encourages readers and investors to supplement the information in these reports with independent research and other pro advice. LiquidTycoon has agreed to be compensated one hundred fifty thousand dollars for a one month investor awareness program by a third party for ECTE. All information on featured companies is provided by the companies profiled, or is available from public sources and LiquidTycoon makes no representations, warranties or guarantees as to the accuracy or completeness of
the disclosure by the profiled companies. This is not a solicitation to or sell any securities. Any claims or Statements should be deemed apocryphal. LiquidTycoon, nor any of its affiliates are not registered investment advisors or a broker dealers.
|
|
